ID   TFR1_HUMAN              Reviewed;         760 AA.
AC   P02786; D3DXB0; Q1HE24; Q59G55; Q9UCN0; Q9UCU5; Q9UDF9; Q9UK21;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2006, sequence version 2.
DT   10-MAY-2017, entry version 212.
DE   RecName: Full=Transferrin receptor protein 1;
DE            Short=TR;
DE            Short=TfR;
DE            Short=TfR1;
DE            Short=Trfr;
DE   AltName: Full=T9;
DE   AltName: Full=p90;
DE   AltName: CD_antigen=CD71;
DE   Contains:
DE     RecName: Full=Transferrin receptor protein 1, serum form;
DE              Short=sTfR;
GN   Name=TFRC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-142.
RX   PubMed=6090955; DOI=10.1038/311675b0;
RA   Schneider C., Owen M.J., Banville D., Williams J.G.;
RT   "Primary structure of human transferrin receptor deduced from the mRNA
RT   sequence.";
RL   Nature 311:675-678(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-142.
RX   PubMed=6094009; DOI=10.1016/0092-8674(84)90004-7;
RA   McClelland A., Kuhn L.C., Ruddle F.H.;
RT   "The human transferrin receptor gene: genomic organization, and the
RT   complete primary structure of the receptor deduced from a cDNA
RT   sequence.";
RL   Cell 39:267-274(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=9358047; DOI=10.1016/S0378-1119(97)00356-9;
RA   Evans P., Kemp J.;
RT   "Exon/intron structure of the human transferrin receptor gene.";
RL   Gene 199:123-131(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RA   Wheeler D.L.;
RT   "Molecular and evolutionary studies of the transferrin receptor.";
RL   Thesis (1999), University of Iowa, United States.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 101-119 (STFR).
RX   PubMed=2229063;
RA   Shih Y.J., Baynes R.D., Hudson B.G., Flowers C.H., Skikne B.S.,
RA   Cook J.D.;
RT   "Serum transferrin receptor is a truncated form of tissue receptor.";
RL   J. Biol. Chem. 265:19077-19081(1990).
RN   [10]
RP   PROTEIN SEQUENCE OF 101-123 (STFR), AND CHARACTERIZATION.
RC   TISSUE=Erythroleukemia;
RX   PubMed=1871153; DOI=10.3181/00379727-197-43276;
RA   Baynes R.D., Shih Y.J., Hudson B.G., Cook J.D.;
RT   "Characterization of transferrin receptor released by K562
RT   erythroleukemia cells.";
RL   Proc. Soc. Exp. Biol. Med. 197:416-423(1991).
RN   [11]
RP   PROTEIN SEQUENCE OF 288-302; 694-708 AND 721-730.
RC   TISSUE=Prostatic carcinoma;
RX   PubMed=7864799; DOI=10.1042/bj3060129;
RA   Coppolino M., Migliorini M., Argraves W.S., Dedhar S.;
RT   "Identification of a novel form of the alpha 3 integrin subunit:
RT   covalent association with transferrin receptor.";
RL   Biochem. J. 306:129-134(1995).
RN   [12]
RP   PROTEIN SEQUENCE OF 680-696.
RX   PubMed=1380674; DOI=10.1038/358764a0;
RA   Chicz R.M., Urban R.G., Lane W.S., Gorga J.C., Stern L.J.,
RA   Vignali D.A.A., Strominger J.L.;
RT   "Predominant naturally processed peptides bound to HLA-DR1 are derived
RT   from MHC-related molecules and are heterogeneous in size.";
RL   Nature 358:764-768(1992).
RN   [13]
RP   FUNCTION.
RX   PubMed=3568132; DOI=10.1016/0092-8674(87)90295-9;
RA   Rothenberger S., Iacopetta B.J., Kuhn L.C.;
RT   "Endocytosis of the transferrin receptor requires the cytoplasmic
RT   domain but not its phosphorylation site.";
RL   Cell 49:423-431(1987).
RN   [14]
RP   PALMITOYLATION AT CYS-62.
RX   PubMed=3582362;
RA   Jing S., Trowbridge I.S.;
RT   "Identification of the intermolecular disulfide bonds of the human
RT   transferrin receptor and its lipid-attachment site.";
RL   EMBO J. 6:327-331(1987).
RN   [15]
RP   MUTAGENESIS OF CYSTEINE RESIDUES INVOLVED IN INTERMOLECULAR BONDS.
RX   PubMed=2507316;
RA   Alvarez E., Girones N., Davis R.J.;
RT   "Intermolecular disulfide bonds are not required for the expression of
RT   the dimeric state and functional activity of the transferrin
RT   receptor.";
RL   EMBO J. 8:2231-2240(1989).
RN   [16]
RP   MUTAGENESIS OF TYR-20.
RX   PubMed=2327986; DOI=10.1042/bj2670031;
RA   Alvarez E., Girones N., Davis R.J.;
RT   "A point mutation in the cytoplasmic domain of the transferrin
RT   receptor inhibits endocytosis.";
RL   Biochem. J. 267:31-35(1990).
RN   [17]
RP   INTERNALIZATION SEQUENCE, AND MUTAGENESIS OF TYR-20.
RX   PubMed=2298808; DOI=10.1083/jcb.110.2.283;
RA   Jing S., Spencer T., Miller K., Hopkins C., Trowbridge I.S.;
RT   "Role of the human transferrin receptor cytoplasmic domain in
RT   endocytosis: localization of a specific signal sequence for
RT   internalization.";
RL   J. Cell Biol. 110:283-294(1990).
RN   [18]
RP   GLYCOSYLATION AT THR-104.
RX   PubMed=1421756; DOI=10.1093/glycob/2.4.345;
RA   Do S.-I., Cummings R.D.;
RT   "Presence of O-linked oligosaccharide on a threonine residue in the
RT   human transferrin receptor.";
RL   Glycobiology 2:345-353(1992).
RN   [19]
RP   GLYCOSYLATION AT THR-104.
RX   PubMed=1421757; DOI=10.1093/glycob/2.4.355;
RA   Hayes G.R., Enns C.A., Lucas J.J.;
RT   "Identification of the O-linked glycosylation site of the human
RT   transferrin receptor.";
RL   Glycobiology 2:355-359(1992).
RN   [20]
RP   MUTAGENESIS OF 20-TYR--PHE-23; TYR-20; THR-21 AND PHE-23.
RX   PubMed=8408022;
RA   Collawn J.F., Lai A., Domingo D.L., Fitch M., Hatton S.,
RA   Trowbridge I.S.;
RT   "YTRF is the conserved internalization signal of the transferrin
RT   receptor, and a second YTRF signal at position 31-34 enhances
RT   endocytosis.";
RL   J. Biol. Chem. 268:21686-21692(1993).
RN   [21]
RP   STRUCTURE OF CARBOHYDRATES ON ASN-727.
RX   PubMed=7780197; DOI=10.1093/glycob/5.2.227;
RA   Hayes G.R., Williams A., Costello C.E., Enns C.A., Lucas J.J.;
RT   "The critical glycosylation site of human transferrin receptor
RT   contains a high-mannose oligosaccharide.";
RL   Glycobiology 5:227-232(1995).
RN   [22]
RP   IDENTIFICATION OF LIGAND-BINDING DOMAIN.
RX   PubMed=8631371; DOI=10.1111/j.1432-1033.1996.0009u.x;
RA   Buchegger F., Trowbridge I.S., Liu L.F., White S., Collawn J.F.;
RT   "Functional analysis of human/chicken transferrin receptor chimeras
RT   indicates that the carboxy-terminal region is important for ligand
RT   binding.";
RL   Eur. J. Biochem. 235:9-17(1996).
RN   [23]
RP   MUTAGENESIS OF ARG-646; GLY-647 AND ASP-648.
RX   PubMed=10377239; DOI=10.1042/bj3410011;
RA   Dubljevic V., Sali A., Goding J.W.;
RT   "A conserved RGD (Arg-Gly-Asp) motif in the transferrin receptor is
RT   required for binding to transferrin.";
RL   Biochem. J. 341:11-14(1999).
RN   [24]
RP   MUTAGENESIS.
RX   PubMed=11800564; DOI=10.1006/jmbi.2001.5048;
RA   West A.P. Jr., Giannetti A.M., Herr A.B., Bennett M.J., Nangiana J.S.,
RA   Pierce J.R., Weiner L.P., Snow P.M., Bjorkman P.J.;
RT   "Mutational analysis of the transferrin receptor reveals overlapping
RT   HFE and transferrin binding sites.";
RL   J. Mol. Biol. 313:385-397(2001).
RN   [25]
RP   INTERACTION WITH SH3BP4.
RX   PubMed=16325581; DOI=10.1016/j.cell.2005.10.021;
RA   Tosoni D., Puri C., Confalonieri S., Salcini A.E., De Camilli P.,
RA   Tacchetti C., Di Fiore P.P.;
RT   "TTP specifically regulates the internalization of the transferrin
RT   receptor.";
RL   Cell 123:875-888(2005).
RN   [26]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-251.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [28]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH MACHUPO VIRUS
RP   PROTEIN GLYCOPROTEIN COMPLEX.
RX   PubMed=17287727; DOI=10.1038/nature05539;
RA   Radoshitzky S.R., Abraham J., Spiropoulou C.F., Kuhn J.H., Nguyen D.,
RA   Li W., Nagel J., Schmidt P.J., Nunberg J.H., Andrews N.C., Farzan M.,
RA   Choe H.;
RT   "Transferrin receptor 1 is a cellular receptor for New World
RT   haemorrhagic fever arenaviruses.";
RL   Nature 446:92-96(2007).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [31]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH GUANARITO VIRUS
RP   GLYCOPROTEIN COMPLEX, INTERACTION WITH JUNIN VIRUS GLYCOPROTEIN
RP   COMPLEX, AND INTERACTION WITH MACHUPO VIRUS GLYCOPROTEIN COMPLEX.
RX   PubMed=18268337; DOI=10.1073/pnas.0709254105;
RA   Radoshitzky S.R., Kuhn J.H., Spiropoulou C.F., Albarino C.G.,
RA   Nguyen D.P., Salazar-Bravo J., Dorfman T., Lee A.S., Wang E.,
RA   Ross S.R., Choe H., Farzan M.;
RT   "Receptor determinants of zoonotic transmission of New World
RT   hemorrhagic fever arenaviruses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2664-2669(2008).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-251 AND ASN-727.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-251.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [40]
RP   ELECTRON MICROSCOPY, AND PHOSPHORYLATION AT SER-24.
RX   PubMed=9782058; DOI=10.1016/S0969-2126(98)00124-5;
RA   Fuchs H., Luecken W., Tauber R., Engel A.;
RT   "Structural model of phospholipid-reconstituted human transferrin
RT   receptor derived by electron microscopy.";
RL   Structure 6:1235-1243(1998).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 121-760.
RX   PubMed=10531064; DOI=10.1126/science.286.5440.779;
RA   Lawrence C.M., Ray S., Babyonyshev M., Galluser R., Borhani D.W.,
RA   Harrison S.C.;
RT   "Crystal structure of the ectodomain of human transferrin receptor.";
RL   Science 286:779-782(1999).
RN   [42]
RP   VARIANT SER-142.
RX   PubMed=11702220; DOI=10.1007/s004390100599;
RA   Douabin-Gicquel V., Soriano N., Ferran H., Wojcik F., Palierne E.,
RA   Tamim S., Jovelin T., McKie A.T., Le Gall J.-Y., David V., Mosser J.;
RT   "Identification of 96 single nucleotide polymorphisms in eight genes
RT   involved in iron metabolism: efficiency of bioinformatic extraction
RT   compared with a systematic sequencing approach.";
RL   Hum. Genet. 109:393-401(2001).
RN   [43]
RP   INVOLVEMENT IN IMD46, VARIANT IMD46 HIS-20, CHARACTERIZATION OF
RP   VARIANT IMD46 HIS-20, FUNCTION, AND INTERACTION WITH STEAP3.
RX   PubMed=26642240; DOI=10.1038/ng.3465;
RA   Jabara H.H., Boyden S.E., Chou J., Ramesh N., Massaad M.J., Benson H.,
RA   Bainter W., Fraulino D., Rahimov F., Sieff C., Liu Z.J.,
RA   Alshemmari S.H., Al-Ramadi B.K., Al-Dhekri H., Arnaout R.,
RA   Abu-Shukair M., Vatsayan A., Silver E., Ahuja S., Davies E.G.,
RA   Sola-Visner M., Ohsumi T.K., Andrews N.C., Notarangelo L.D.,
RA   Fleming M.D., Al-Herz W., Kunkel L.M., Geha R.S.;
RT   "A missense mutation in TFRC, encoding transferrin receptor 1, causes
RT   combined immunodeficiency.";
RL   Nat. Genet. 48:74-78(2016).
CC   -!- FUNCTION: Cellular uptake of iron occurs via receptor-mediated
CC       endocytosis of ligand-occupied transferrin receptor into
CC       specialized endosomes. Endosomal acidification leads to iron
CC       release. The apotransferrin-receptor complex is then recycled to
CC       the cell surface with a return to neutral pH and the concomitant
CC       loss of affinity of apotransferrin for its receptor. Transferrin
CC       receptor is necessary for development of erythrocytes and the
CC       nervous system (By similarity). A second ligand, the heditary
CC       hemochromatosis protein HFE, competes for binding with transferrin
CC       for an overlapping C-terminal binding site. Positively regulates T
CC       and B cell proliferation through iron uptake (PubMed:26642240).
CC       {ECO:0000250, ECO:0000269|PubMed:26642240,
CC       ECO:0000269|PubMed:3568132}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for new-world
CC       arenaviruses: Guanarito, Junin and Machupo virus.
CC       {ECO:0000269|PubMed:17287727, ECO:0000269|PubMed:18268337}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Binds one transferrin or HFE
CC       molecule per subunit. Binds the HLA class II histocompatibility
CC       antigen, DR1. Interacts with SH3BP3. Interacts with STEAP3;
CC       facilitates TFRC endocytosis in erythroid precursor cells
CC       (PubMed:26642240). {ECO:0000269|PubMed:16325581,
CC       ECO:0000269|PubMed:26642240}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Guanarito, Junin and
CC       Machupo arenavirus glycoprotein complex (PubMed:17287727,
CC       PubMed:18268337). {ECO:0000269|PubMed:17287727,
CC       ECO:0000269|PubMed:18268337}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-355727, EBI-355727;
CC       P02768:ALB; NbExp=2; IntAct=EBI-355727, EBI-714423;
CC       Q30201:HFE; NbExp=3; IntAct=EBI-355727, EBI-1028850;
CC       O43765:SGTA; NbExp=5; IntAct=EBI-355727, EBI-347996;
CC       Q9P0V3:SH3BP4; NbExp=6; IntAct=EBI-355727, EBI-1049513;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17081065};
CC       Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:17081065}. Melanosome
CC       {ECO:0000269|PubMed:17081065}. Note=Identified by mass
CC       spectrometry in melanosome fractions from stage I to stage IV.
CC       {ECO:0000269|PubMed:17081065}.
CC   -!- SUBCELLULAR LOCATION: Transferrin receptor protein 1, serum form:
CC       Secreted {ECO:0000269|PubMed:17081065}.
CC   -!- INDUCTION: Regulated by cellular iron levels through binding of
CC       the iron regulatory proteins, IRP1 and IRP2, to iron-responsive
CC       elements in the 3'-UTR. Up-regulated upon mitogenic stimulation.
CC   -!- PTM: N- and O-glycosylated, phosphorylated and palmitoylated. The
CC       serum form is only glycosylated. {ECO:0000269|PubMed:1421756,
CC       ECO:0000269|PubMed:1421757, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973,
CC       ECO:0000269|PubMed:3582362}.
CC   -!- PTM: Proteolytically cleaved on Arg-100 to produce the soluble
CC       serum form (sTfR).
CC   -!- PTM: Palmitoylated on both Cys-62 and Cys-67. Cys-62 seems to be
CC       the major site of palmitoylation. {ECO:0000269|PubMed:3582362}.
CC   -!- DISEASE: Immunodeficiency 46 (IMD46) [MIM:616740]: An autosomal
CC       recessive primary immunodeficiency disorder characterized by
CC       early-onset chronic diarrhea, recurrent infections, hypo- or
CC       agammaglobulinemia, normal lymphocyte counts, intermittent
CC       neutropenia, and intermittent thrombocytopenia.
CC       {ECO:0000269|PubMed:26642240}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Serum transferrin receptor (sTfR) is used as a
CC       means of detecting erythropoietin (EPO) misuse by athletes and as
CC       a diagnostic test for anemia resulting from a number of conditions
CC       including rheumatoid arthritis, pregnancy, irritable bowel
CC       syndrome and in HIV patients.
CC   -!- MISCELLANEOUS: Canine and feline parvoviruses bind human and
CC       feline transferrin receptors and use these receptors to enter and
CC       infect cells.
CC   -!- SIMILARITY: Belongs to the peptidase M28 family. M28B subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92491.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TFRCID259ch3q29.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X01060; CAA25527.1; -; mRNA.
DR   EMBL; M11507; AAA61153.1; -; mRNA.
DR   EMBL; AF187320; AAF04564.1; -; Genomic_DNA.
DR   EMBL; AB209254; BAD92491.1; ALT_INIT; mRNA.
DR   EMBL; DQ496099; ABF47088.1; -; Genomic_DNA.
DR   EMBL; CH471191; EAW53670.1; -; Genomic_DNA.
DR   EMBL; CH471191; EAW53673.1; -; Genomic_DNA.
DR   EMBL; BC001188; AAH01188.1; -; mRNA.
DR   CCDS; CCDS3312.1; -.
DR   PIR; A93343; JXHU.
DR   RefSeq; NP_001121620.1; NM_001128148.2.
DR   RefSeq; NP_001300894.1; NM_001313965.1.
DR   RefSeq; NP_001300895.1; NM_001313966.1.
DR   RefSeq; NP_003225.2; NM_003234.3.
DR   UniGene; Hs.529618; -.
DR   PDB; 1CX8; X-ray; 3.20 A; A/B/C/D/E/F/G/H=122-760.
DR   PDB; 1DE4; X-ray; 2.80 A; C/F/I=121-760.
DR   PDB; 1SUV; EM; 7.50 A; A/B=122-760.
DR   PDB; 2NSU; EM; 27.00 A; A/B=122-760.
DR   PDB; 3KAS; X-ray; 2.40 A; A=121-760.
DR   PDB; 3S9L; X-ray; 3.22 A; A/B=120-760.
DR   PDB; 3S9M; X-ray; 3.32 A; A/B=120-760.
DR   PDB; 3S9N; X-ray; 3.25 A; A/B=120-760.
DR   PDBsum; 1CX8; -.
DR   PDBsum; 1DE4; -.
DR   PDBsum; 1SUV; -.
DR   PDBsum; 2NSU; -.
DR   PDBsum; 3KAS; -.
DR   PDBsum; 3S9L; -.
DR   PDBsum; 3S9M; -.
DR   PDBsum; 3S9N; -.
DR   ProteinModelPortal; P02786; -.
DR   SMR; P02786; -.
DR   BioGrid; 112895; 82.
DR   DIP; DIP-2736N; -.
DR   IntAct; P02786; 61.
DR   MINT; MINT-4999032; -.
DR   STRING; 9606.ENSP00000353224; -.
DR   DrugBank; DB05260; Gallium nitrate.
DR   MEROPS; M28.972; -.
DR   iPTMnet; P02786; -.
DR   PhosphoSitePlus; P02786; -.
DR   SwissPalm; P02786; -.
DR   UniCarbKB; P02786; -.
DR   BioMuta; TFRC; -.
DR   DMDM; 108935939; -.
DR   EPD; P02786; -.
DR   MaxQB; P02786; -.
DR   PaxDb; P02786; -.
DR   PeptideAtlas; P02786; -.
DR   PRIDE; P02786; -.
DR   DNASU; 7037; -.
DR   Ensembl; ENST00000360110; ENSP00000353224; ENSG00000072274.
DR   Ensembl; ENST00000392396; ENSP00000376197; ENSG00000072274.
DR   GeneID; 7037; -.
DR   KEGG; hsa:7037; -.
DR   UCSC; uc003fvz.5; human.
DR   CTD; 7037; -.
DR   DisGeNET; 7037; -.
DR   GeneCards; TFRC; -.
DR   HGNC; HGNC:11763; TFRC.
DR   HPA; CAB000153; -.
DR   HPA; HPA028598; -.
DR   MalaCards; TFRC; -.
DR   MIM; 190010; gene.
DR   MIM; 616740; phenotype.
DR   neXtProt; NX_P02786; -.
DR   OpenTargets; ENSG00000072274; -.
DR   PharmGKB; PA36478; -.
DR   eggNOG; KOG2195; Eukaryota.
DR   eggNOG; COG2234; LUCA.
DR   GeneTree; ENSGT00550000074421; -.
DR   HOVERGEN; HBG023177; -.
DR   InParanoid; P02786; -.
DR   KO; K06503; -.
DR   OMA; DNSHVEM; -.
DR   OrthoDB; EOG091G02ZM; -.
DR   PhylomeDB; P02786; -.
DR   TreeFam; TF312981; -.
DR   Reactome; R-HSA-432722; Golgi Associated Vesicle Biogenesis.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-917977; Transferrin endocytosis and recycling.
DR   SIGNOR; P02786; -.
DR   ChiTaRS; TFRC; human.
DR   EvolutionaryTrace; P02786; -.
DR   GeneWiki; TFRC; -.
DR   GenomeRNAi; 7037; -.
DR   PRO; PR:P02786; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000072274; -.
DR   CleanEx; HS_TFRC; -.
DR   ExpressionAtlas; P02786; baseline and differential.
DR   Genevisible; P02786; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB.
DR   GO; GO:0030665; C:clathrin-coated vesicle membrane; TAS:Reactome.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:MGI.
DR   GO; GO:0005768; C:endosome; IDA:MGI.
DR   GO; GO:0010008; C:endosome membrane; IDA:CAFA.
DR   GO; GO:0009897; C:external side of plasma membrane; IGI:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:1990712; C:HFE-transferrin receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IGI:BHF-UCL.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:CAFA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0055037; C:recycling endosome; IDA:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0004998; F:transferrin receptor activity; TAS:ProtInc.
DR   GO; GO:0033570; F:transferrin transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006879; P:cellular iron ion homeostasis; TAS:ProtInc.
DR   GO; GO:0035690; P:cellular response to drug; IDA:MGI.
DR   GO; GO:0097286; P:iron ion import; IDA:UniProtKB.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045780; P:positive regulation of bone resorption; IEA:Ensembl.
DR   GO; GO:0045830; P:positive regulation of isotype switching; IDA:UniProtKB.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IDA:UniProtKB.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   GO; GO:0033572; P:transferrin transport; IDA:UniProtKB.
DR   Gene3D; 1.20.930.40; -; 1.
DR   InterPro; IPR003137; PA_domain.
DR   InterPro; IPR007484; Peptidase_M28.
DR   InterPro; IPR029513; TfR.
DR   InterPro; IPR007365; TFR-like_dimer_dom.
DR   PANTHER; PTHR10404:SF54; PTHR10404:SF54; 1.
DR   Pfam; PF02225; PA; 1.
DR   Pfam; PF04389; Peptidase_M28; 1.
DR   Pfam; PF04253; TFR_dimer; 1.
DR   SUPFAM; SSF47672; SSF47672; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Endocytosis; Glycoprotein; Host cell receptor for virus entry;
KW   Host-virus interaction; Lipoprotein; Membrane; Palmitate;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Secreted;
KW   Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN         1    760       Transferrin receptor protein 1.
FT                                /FTId=PRO_0000174132.
FT   CHAIN       101    760       Transferrin receptor protein 1, serum
FT                                form.
FT                                /FTId=PRO_0000292265.
FT   TOPO_DOM      1     67       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     68     88       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     89    760       Extracellular. {ECO:0000255}.
FT   DOMAIN      223    313       PA.
FT   REGION        1     67       Mediates interaction with SH3BP4.
FT                                {ECO:0000269|PubMed:16325581}.
FT   REGION      569    760       Ligand-binding.
FT   MOTIF        20     23       Endocytosis signal.
FT   MOTIF        58     61       Stop-transfer sequence.
FT   MOTIF       646    648       Cell attachment site; required for
FT                                binding to transferrin.
FT   SITE        100    101       Cleavage; by trypsin; to produce soluble
FT                                form.
FT   MOD_RES      10     10       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      19     19       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62351}.
FT   MOD_RES      20     20       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES      21     21       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES      24     24       Phosphoserine.
FT                                {ECO:0000269|PubMed:9782058}.
FT   LIPID        62     62       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:3582362}.
FT   LIPID        67     67       S-palmitoyl cysteine.
FT   CARBOHYD    104    104       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:1421756,
FT                                ECO:0000269|PubMed:1421757}.
FT                                /FTId=CAR_000072.
FT   CARBOHYD    251    251       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:1CX8,
FT                                ECO:0000244|PDB:3KAS,
FT                                ECO:0000269|PubMed:10531064,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    317    317       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:1CX8,
FT                                ECO:0000244|PDB:1DE4,
FT                                ECO:0000244|PDB:3S9L,
FT                                ECO:0000244|PDB:3S9M,
FT                                ECO:0000244|PDB:3S9N,
FT                                ECO:0000269|PubMed:10531064}.
FT   CARBOHYD    727    727       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:1CX8,
FT                                ECO:0000244|PDB:3KAS,
FT                                ECO:0000269|PubMed:10531064,
FT                                ECO:0000269|PubMed:19159218}.
FT                                /FTId=CAR_000173.
FT   DISULFID     89     89       Interchain.
FT   DISULFID     98     98       Interchain.
FT   VARIANT      20     20       Y -> H (in IMD46; increases protein
FT                                expression; increases cell surface
FT                                expression on T and B cells; increases
FT                                soluble form level; impairs receptor
FT                                internalization; impairs transferrin
FT                                transport; impairs T and B cell
FT                                proliferation as well as B cell class-
FT                                switching; interacts with STEAP3; doesn't
FT                                affect receptor internalization in
FT                                erythroid precursor cells;
FT                                dbSNP:rs863225436).
FT                                {ECO:0000269|PubMed:26642240}.
FT                                /FTId=VAR_076365.
FT   VARIANT     142    142       G -> S (rare polymorphism;
FT                                dbSNP:rs3817672).
FT                                {ECO:0000269|PubMed:11702220,
FT                                ECO:0000269|PubMed:6090955,
FT                                ECO:0000269|PubMed:6094009}.
FT                                /FTId=VAR_012737.
FT   VARIANT     212    212       L -> V (in dbSNP:rs41301381).
FT                                /FTId=VAR_051806.
FT   VARIANT     420    420       G -> S (in dbSNP:rs41295879).
FT                                /FTId=VAR_051807.
FT   VARIANT     677    677       R -> H (in dbSNP:rs41298067).
FT                                /FTId=VAR_051808.
FT   MUTAGEN       9     12       FSNL->YTRF: Only 80% as active as wild-
FT                                type receptor.
FT   MUTAGEN      20     34       YTRFSLARQVDGDNS->PPGYSLARQVDYTRF: No
FT                                influence on endocytic uptake of the
FT                                receptor.
FT   MUTAGEN      20     23       YTRF->PPGY: Only 16% as active as wild-
FT                                type receptor.
FT                                {ECO:0000269|PubMed:8408022}.
FT   MUTAGEN      20     20       Y->C: Only 35% as active as wild-type
FT                                receptor. {ECO:0000269|PubMed:2298808,
FT                                ECO:0000269|PubMed:2327986,
FT                                ECO:0000269|PubMed:8408022}.
FT   MUTAGEN      20     20       Y->G: Only 20% as active as wild-type
FT                                receptor. {ECO:0000269|PubMed:2298808,
FT                                ECO:0000269|PubMed:2327986,
FT                                ECO:0000269|PubMed:8408022}.
FT   MUTAGEN      21     21       T->F: Only 88% as active as wild-type
FT                                receptor. {ECO:0000269|PubMed:8408022}.
FT   MUTAGEN      21     21       T->TA: Only 14% as active as wild-type
FT                                receptor. {ECO:0000269|PubMed:8408022}.
FT   MUTAGEN      21     21       T->TAA: Only 19% as active as wild-type
FT                                receptor. {ECO:0000269|PubMed:8408022}.
FT   MUTAGEN      23     23       F->Y: Only 48% as active as wild-type
FT                                receptor. {ECO:0000269|PubMed:8408022}.
FT   MUTAGEN      31     34       GDNS->YTRF: 2-fold increase of the
FT                                endocytic uptake of the receptor.
FT   MUTAGEN      47     50       NADN->YTRF: 1.27-fold increase of the
FT                                endocytic uptake of the receptor.
FT   MUTAGEN     619    619       L->A: 20-fold reduced affinity for
FT                                transferrin receptor. No binding to HFE.
FT   MUTAGEN     622    622       V->A: No significant effect on binding to
FT                                transferrin nor HFE.
FT   MUTAGEN     623    623       R->A: No significant effect on binding to
FT                                transferrin nor HFE.
FT   MUTAGEN     629    629       R->A: >5-fold reduced affinity for
FT                                transferrin. >10-fold reduced affinity
FT                                for HFE.
FT   MUTAGEN     640    640       Q->A: No effect on binding to
FT                                transferrin. >10-fold reduced affinity
FT                                for HFE.
FT   MUTAGEN     641    641       W->A: No significant effect on binding to
FT                                transferrin nor HFE.
FT   MUTAGEN     643    643       Y->A: 20-fold reduced affinity for
FT                                transferrin. No binding to HFE.
FT   MUTAGEN     644    644       S->A: No significant effect on binding to
FT                                transferrin nor HFE.
FT   MUTAGEN     646    646       R->A,H: No binding to transferrin.
FT                                {ECO:0000269|PubMed:10377239}.
FT   MUTAGEN     646    646       R->K: 5% binding to transferrin.
FT                                {ECO:0000269|PubMed:10377239}.
FT   MUTAGEN     647    647       G->A: Large effect on affinity for
FT                                transferrin. 4-fold reduced affinity for
FT                                HFE. {ECO:0000269|PubMed:10377239}.
FT   MUTAGEN     648    648       D->A: 16% binding to transferrin.
FT                                {ECO:0000269|PubMed:10377239}.
FT   MUTAGEN     648    648       D->E: 57% binding to transferrin.
FT                                {ECO:0000269|PubMed:10377239}.
FT   MUTAGEN     650    650       F->Q: >5-fold reduced affinity for
FT                                transferrin. >10-fold reduced affinity
FT                                for HFE.
FT   CONFLICT    104    104       T -> K (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    109    109       R -> V (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    123    123       Y -> T (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX       124    136       {ECO:0000244|PDB:3KAS}.
FT   HELIX       140    146       {ECO:0000244|PDB:3KAS}.
FT   TURN        150    152       {ECO:0000244|PDB:3KAS}.
FT   HELIX       160    176       {ECO:0000244|PDB:3KAS}.
FT   STRAND      179    192       {ECO:0000244|PDB:3KAS}.
FT   STRAND      199    204       {ECO:0000244|PDB:3KAS}.
FT   TURN        205    208       {ECO:0000244|PDB:3KAS}.
FT   STRAND      209    214       {ECO:0000244|PDB:3KAS}.
FT   STRAND      220    222       {ECO:0000244|PDB:3S9L}.
FT   STRAND      226    230       {ECO:0000244|PDB:3KAS}.
FT   STRAND      232    234       {ECO:0000244|PDB:3KAS}.
FT   TURN        236    238       {ECO:0000244|PDB:1CX8}.
FT   HELIX       240    244       {ECO:0000244|PDB:3KAS}.
FT   STRAND      245    248       {ECO:0000244|PDB:1CX8}.
FT   STRAND      253    259       {ECO:0000244|PDB:3KAS}.
FT   HELIX       264    272       {ECO:0000244|PDB:3KAS}.
FT   TURN        273    275       {ECO:0000244|PDB:3KAS}.
FT   STRAND      277    282       {ECO:0000244|PDB:3KAS}.
FT   TURN        285    287       {ECO:0000244|PDB:3KAS}.
FT   STRAND      303    306       {ECO:0000244|PDB:3KAS}.
FT   STRAND      308    310       {ECO:0000244|PDB:3S9L}.
FT   STRAND      311    313       {ECO:0000244|PDB:1CX8}.
FT   HELIX       317    319       {ECO:0000244|PDB:1DE4}.
FT   STRAND      334    336       {ECO:0000244|PDB:3KAS}.
FT   HELIX       339    346       {ECO:0000244|PDB:3KAS}.
FT   STRAND      349    352       {ECO:0000244|PDB:3KAS}.
FT   HELIX       355    357       {ECO:0000244|PDB:3KAS}.
FT   STRAND      364    367       {ECO:0000244|PDB:3KAS}.
FT   STRAND      371    377       {ECO:0000244|PDB:3KAS}.
FT   STRAND      380    393       {ECO:0000244|PDB:3KAS}.
FT   STRAND      396    408       {ECO:0000244|PDB:3KAS}.
FT   STRAND      411    413       {ECO:0000244|PDB:3S9N}.
FT   TURN        416    419       {ECO:0000244|PDB:3KAS}.
FT   HELIX       420    438       {ECO:0000244|PDB:3KAS}.
FT   STRAND      445    455       {ECO:0000244|PDB:3KAS}.
FT   HELIX       456    458       {ECO:0000244|PDB:3KAS}.
FT   HELIX       461    469       {ECO:0000244|PDB:3KAS}.
FT   TURN        470    473       {ECO:0000244|PDB:3KAS}.
FT   HELIX       474    476       {ECO:0000244|PDB:3KAS}.
FT   STRAND      478    483       {ECO:0000244|PDB:3KAS}.
FT   STRAND      491    498       {ECO:0000244|PDB:3KAS}.
FT   HELIX       500    502       {ECO:0000244|PDB:3KAS}.
FT   HELIX       503    510       {ECO:0000244|PDB:3KAS}.
FT   TURN        516    518       {ECO:0000244|PDB:3KAS}.
FT   STRAND      520    522       {ECO:0000244|PDB:3KAS}.
FT   HELIX       528    531       {ECO:0000244|PDB:3KAS}.
FT   HELIX       541    546       {ECO:0000244|PDB:3KAS}.
FT   STRAND      552    558       {ECO:0000244|PDB:3KAS}.
FT   TURN        564    567       {ECO:0000244|PDB:3KAS}.
FT   HELIX       573    579       {ECO:0000244|PDB:3KAS}.
FT   HELIX       583    603       {ECO:0000244|PDB:3KAS}.
FT   STRAND      604    606       {ECO:0000244|PDB:3KAS}.
FT   HELIX       613    625       {ECO:0000244|PDB:3KAS}.
FT   HELIX       626    628       {ECO:0000244|PDB:3KAS}.
FT   TURN        629    636       {ECO:0000244|PDB:3KAS}.
FT   HELIX       640    662       {ECO:0000244|PDB:3KAS}.
FT   HELIX       668    680       {ECO:0000244|PDB:3KAS}.
FT   HELIX       682    685       {ECO:0000244|PDB:3KAS}.
FT   STRAND      688    690       {ECO:0000244|PDB:3S9L}.
FT   TURN        692    694       {ECO:0000244|PDB:3KAS}.
FT   TURN        700    702       {ECO:0000244|PDB:3KAS}.
FT   STRAND      705    708       {ECO:0000244|PDB:3S9M}.
FT   HELIX       709    717       {ECO:0000244|PDB:3KAS}.
FT   TURN        718    722       {ECO:0000244|PDB:3S9L}.
FT   HELIX       728    749       {ECO:0000244|PDB:3KAS}.
FT   HELIX       753    755       {ECO:0000244|PDB:1DE4}.
SQ   SEQUENCE   760 AA;  84871 MW;  C886F14000D90154 CRC64;
     MMDQARSAFS NLFGGEPLSY TRFSLARQVD GDNSHVEMKL AVDEEENADN NTKANVTKPK
     RCSGSICYGT IAVIVFFLIG FMIGYLGYCK GVEPKTECER LAGTESPVRE EPGEDFPAAR
     RLYWDDLKRK LSEKLDSTDF TGTIKLLNEN SYVPREAGSQ KDENLALYVE NQFREFKLSK
     VWRDQHFVKI QVKDSAQNSV IIVDKNGRLV YLVENPGGYV AYSKAATVTG KLVHANFGTK
     KDFEDLYTPV NGSIVIVRAG KITFAEKVAN AESLNAIGVL IYMDQTKFPI VNAELSFFGH
     AHLGTGDPYT PGFPSFNHTQ FPPSRSSGLP NIPVQTISRA AAEKLFGNME GDCPSDWKTD
     STCRMVTSES KNVKLTVSNV LKEIKILNIF GVIKGFVEPD HYVVVGAQRD AWGPGAAKSG
     VGTALLLKLA QMFSDMVLKD GFQPSRSIIF ASWSAGDFGS VGATEWLEGY LSSLHLKAFT
     YINLDKAVLG TSNFKVSASP LLYTLIEKTM QNVKHPVTGQ FLYQDSNWAS KVEKLTLDNA
     AFPFLAYSGI PAVSFCFCED TDYPYLGTTM DTYKELIERI PELNKVARAA AEVAGQFVIK
     LTHDVELNLD YERYNSQLLS FVRDLNQYRA DIKEMGLSLQ WLYSARGDFF RATSRLTTDF
     GNAEKTDRFV MKKLNDRVMR VEYHFLSPYV SPKESPFRHV FWGSGSHTLP ALLENLKLRK
     QNNGAFNETL FRNQLALATW TIQGAANALS GDVWDIDNEF
//
